Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brolucizumab in polypoidal choroidal vasculopathy
NCT05666804Phase 3Completed
- Sponsor
- Novartis
- Start
- Feb 2023
- Primary completion
- Sep 2025
- Modality
- scFv Fragments, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of brolucizumab in polypoidal choroidal vasculopathy (PCV), sponsored by Novartis. Started Feb 2023; status: completed.
02
Drugs
brolucizumab
03
Conditions
polypoidal choroidal vasculopathy (PCV)
Beyond the preview
Go deeper on NCT05666804.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05666804.